The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics for uncomplicated urinary tract infections (uUTIs) in over 20 yea
In a landmark development, world leaders meeting at the United Nations officially adopted a political declaration on antimicrobial resistance (AMR), which includes a target of a 10% cut in
UK biotech F2G has raised $100 million as it prepares to refile its olorofim candidate for invasive fungal infections, which was turned down last year by the FDA.
The non-profit International Society for Infectious Diseases (ISID) has published a set of six priorities focusing on the challenges faced by low- and middle-income countries (LMICs) ahead
GSK has become the first founding partner of the new Fleming Initiative, which aims to tackle the rising threat of antimicrobial resistance (AMR) and is also backed by the
GSK has expanded a collaboration with BioVersys on a new drug candidate for tuberculosis (TB) and contributed to an extension to the Swiss biotech’s third-round financing.